This open enrollment, choose a plan that includes access to our world-class providers. Get better care now

Menu
Search

UCSD Research Reveals Mechanism Involved With Type of Fatal Epilepsy

 

September 19, 2005  |  

Researchers at University of California, San Diego (UCSD) have found that Lafora disease, an inherited form of epilepsy that results in death by the age of 30, can be caused by mutations in a gene that regulates the concentration of the protein laforin. These findings are reported in the current issue of Proceedings of the National Academy of Sciences (PNAS).

Lafora disease is characterized by normal development for the first decade of life, followed by an initial seizure in the second decade, progressively worsening seizures, early dementia, and death within 10 years of onset. Medications can ease the severity of initial symptoms, but there is no long-term treatment or cure for the disease.

A puzzling aspect of the disease is the accumulation of starch-/glycogen-like granules in most tissues of Lafora disease patients. Thus, researchers have long thought that a defect in glycogen metabolism is intimately linked to the disease. Recessive mutations in two genes have been shown to cause Lafora disease. The genes encode the proteins laforin and malin, but the molecular mechanism defining how loss of laforin or malin causes Lafora disease has remained unclear.

Jack E. Dixon, Ph.D., UCSD dean of scientific affairs and professor of pharmacology, and colleagues at UCSD investigated the role of malin in Lafora disease and found that malin physically interacts with laforin and regulates laforin’s concentration by marking it for degradation. Their results show that approximately 40 percent of patients with Lafora disease have mutations in malin that render it unable to mark laforin for degradation. This increase in laforin may lead to Lafora disease through aberrant glycogen metabolism.

This work establishes a few testable models as to the molecular mechanism of the disease. Dixon and colleagues are currently designing experiments to test these models with the hope of gaining the necessary insights to develop potential therapies for Lafora disease.

Co-authors are Matthew S. Gentry, Ph.D., and Carolyn A. Worby, Ph.D., both of the UCSD Department of Pharmacy. This research was funded by the National Institutes of Health.

#  #  #

News Media Contact: Leslie Franz or Nancy Stringer, 619-543-6163, healthscicomm@ucsd.edu

Note to broadcast and cable producers: UCSD provides an on-campus satellite uplink facility for live or pre-recorded television interviews.  Please
phone, or e-mail, the media contact listed above to arrange an interview.

UCSD Health Sciences Communications HealthBeat: /news/


Related_Specialties


Media Contact

Share This Article


Related News

11/20/2019
UC San Diego researchers describe how circular extrachromosomal DNA in cancer cells boosts aggressiveness and resistance to therapies.
11/14/2019
Researchers identified non-coding regions of the human genome that control the development and function of four brain cell types and mapped genetic risk variants for psychiatric diseases. They found t ...
11/13/2019
Researchers at University of California San Diego School of Medicine, as well as a diverse team of cardiologists and physicists, developed a machine learning algorithm to predict the life expectancy i ...
11/13/2019
UC San Diego researchers linked a gut bacteria toxin to worse clinical outcomes in patients with alcoholic liver disease, and discovered that treatment with bacteriophages clears the bacteria and elim ...



Follow Us